Literature DB >> 17704261

My approach to and thoughts on the typing of ovarian carcinomas.

W G McCluggage1.   

Abstract

Ovarian carcinomas of epithelial type comprise a heterogeneous group of neoplasms, each with a different underlying pathogenesis and natural behaviour. Accurate classification of ovarian carcinomas is important since each type may be associated with a different behaviour, natural history and outcome. Precise classification is also critical to determine whether alternative therapeutic strategies are appropriate for different tumour types. Previous studies have shown significant interobserver variation in the typing of ovarian carcinomas. There are several areas where there are particular difficulties; these include the distinction between high-grade serous and endometrioid adenocarcinomas and the distinction between a true clear cell carcinoma and clear cell areas within other adenocarcinomas. This review details my approach to the typing of ovarian carcinomas. Morphological assessment, which remains the mainstay in diagnosis, can be supplemented by immunohistochemistry which, for example, is useful in the distinction between serous carcinomas (WT1 positive) and other carcinomas (generally WT1 negative). In recent years, there has been emerging new information regarding the major underlying molecular events in several types of ovarian carcinoma. This has resulted in the acceptance that there are two distinct types of ovarian serous carcinoma. These are termed low-grade and high-grade serous carcinoma, but represent two distinct tumour types rather than low-grade and high-grade variants of the same neoplasm. The integration of clinical, morphological and molecular data has resulted in a more precise classification of ovarian carcinomas and has resulted in the proposal for a broad dualistic pathway of ovarian epithelial carcinogenesis with, in general, low-grade type 1 tumours evolving from benign and borderline neoplasms through a well-defined adenoma-carcinoma sequence, and high-grade type 2 neoplasms arising from an, as yet, undefined precursor lesion.

Entities:  

Mesh:

Year:  2007        PMID: 17704261     DOI: 10.1136/jcp.2007.049478

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  37 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

3.  Oral contraceptives decrease the prevalence of ovarian cancer in the hen.

Authors:  Lindsey S Treviño; Elizabeth L Buckles; Patricia A Johnson
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

4.  FGF18 as a potential biomarker in serous and mucinous ovarian tumors.

Authors:  Saba El-Gendi; Eman Abdelzaher; Mohamed Farouk Mostafa; Ghada Abu Sheasha
Journal:  Tumour Biol       Date:  2015-10-02

5.  The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor.

Authors:  João Lobo; Bianca Machado; Renata Vieira; Carla Bartosch
Journal:  Virchows Arch       Date:  2016-10-18       Impact factor: 4.064

6.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

Review 7.  Ovarian cancer update: lessons from morphology, molecules, and mice.

Authors:  Kathleen R Cho
Journal:  Arch Pathol Lab Med       Date:  2009-11       Impact factor: 5.534

8.  Importance of spondin 1 and cellular retinoic acid binding protein 1 in the clinical diagnosis of ovarian cancer.

Authors:  Ting-Ting Jiao; Ye-Min Zhang; Lin Yao; Yuan Gao; Jian Sun; Dong-Fang Zou; Guo-Ping Wu; Dan Wang; Jun Ou; Ning Hui
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

9.  Reproductive characteristics in relation to ovarian cancer risk by histologic pathways.

Authors:  M A Merritt; M De Pari; A F Vitonis; L J Titus; D W Cramer; K L Terry
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

10.  S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.

Authors:  Melissa S DeRycke; John D Andersen; Katherine M Harrington; Stefan E Pambuccian; Steve E Kalloger; Kristin L M Boylan; Peter A Argenta; Amy P N Skubitz
Journal:  Am J Clin Pathol       Date:  2009-12       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.